« Bernard Munos Rides Again |
| Read the Comments »
August 8, 2011
A couple of weeks ago, we had this discussion about the cost-effectiveness of drugs for multiple sclerosis. It was pointed out that Novartis's new Gilenya (fingolimod) is priced even higher than the drugs in the study that found that MS drugs are among the priciest in the world for their medical benefit.
Now the United Kingdom's NICE has said that Gilenya has not (so far) shown enough efficacy to justify its price. There's going to be a lot of emotionally engaged comment on both sides of this issue, but people should have been able to see this coming. And by "people", yes, I also mean Novartis.
+ TrackBacks (0) | Category: General Scientific News | The Central Nervous System
POST A COMMENT
- RELATED ENTRIES
- Merck's Aftermath
- Models and Reality
- Rewriting History at the Smithsonian?
- The FDA: Too Loose, Or Appropriately Brave?
- More Magic Methyls, Please
- Totaling Up a Job Search
- Humble Enzyme Dodges Spotlight
- Unraveling An Off-Rate